uniQure (NASDAQ:QURE) Price Target Cut to $6.00 by Analysts at Mizuho

uniQure (NASDAQ:QURE) had its price target reduced by Mizuho from $7.00 to $6.00 in a report published on Wednesday, Benzinga reports. Mizuho currently has a neutral rating on the biotechnology company’s stock.

QURE has been the topic of a number of other research reports. HC Wainwright lowered their price objective on uniQure from $30.00 to $25.00 and set a buy rating on the stock in a research note on Friday, March 1st. The Goldman Sachs Group lowered uniQure from a buy rating to a neutral rating and decreased their price target for the company from $63.00 to $8.00 in a research note on Thursday, February 29th. StockNews.com raised uniQure to a sell rating in a research note on Friday, March 1st. Finally, Royal Bank of Canada reaffirmed an outperform rating and issued a $28.00 price target on shares of uniQure in a research note on Tuesday, January 16th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of Moderate Buy and an average price target of $31.91.

uniQure Price Performance

Shares of uniQure stock traded up $0.01 on Wednesday, reaching $4.90. The company’s stock had a trading volume of 71,687 shares, compared to its average volume of 914,806. The company has a market capitalization of $234.41 million, a P/E ratio of -0.75 and a beta of 0.98. uniQure has a 52-week low of $4.25 and a 52-week high of $22.48. The stock has a 50-day moving average price of $5.00 and a 200-day moving average price of $5.88. The company has a quick ratio of 8.68, a current ratio of 8.85 and a debt-to-equity ratio of 0.49.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported ($1.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.54) by $0.01. The firm had revenue of $6.69 million for the quarter, compared to analyst estimates of $3.20 million. uniQure had a negative return on equity of 99.31% and a negative net margin of 1,947.09%. Analysts expect that uniQure will post -4.49 EPS for the current year.

Insider Transactions at uniQure

In other news, COO Pierre Caloz sold 9,455 shares of the company’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $6.47, for a total transaction of $61,173.85. Following the completion of the transaction, the chief operating officer now directly owns 85,643 shares of the company’s stock, valued at approximately $554,110.21. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, COO Pierre Caloz sold 9,455 shares of the company’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $6.47, for a total transaction of $61,173.85. Following the completion of the transaction, the chief operating officer now directly owns 85,643 shares of the company’s stock, valued at approximately $554,110.21. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Christian Klemt sold 15,906 shares of the company’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $6.38, for a total value of $101,480.28. Following the completion of the sale, the chief financial officer now directly owns 116,948 shares of the company’s stock, valued at $746,128.24. The disclosure for this sale can be found here. In the last ninety days, insiders sold 53,265 shares of company stock valued at $339,845. 4.74% of the stock is currently owned by corporate insiders.

Institutional Trading of uniQure

A number of large investors have recently made changes to their positions in QURE. Headlands Technologies LLC acquired a new stake in uniQure during the 3rd quarter worth approximately $31,000. China Universal Asset Management Co. Ltd. lifted its position in uniQure by 222.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,258 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 4,315 shares during the period. Nomura Holdings Inc. acquired a new stake in uniQure during the 3rd quarter worth approximately $67,000. Laurion Capital Management LP acquired a new stake in uniQure during the 3rd quarter worth approximately $73,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in uniQure during the 4th quarter worth approximately $86,000. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.